Imidazopyridines syk inhibitors
AssigneeGilead Connecticut, Inc.
InventorsPeter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Seung H. Lee, Scott A. Mitchell, Aaron C. Schmitt, Jianjun Xu, Zhongdong Zhao
Life of this patent
Estimating the term…
Abstract
Certain imidazopyridines (I) and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.
Claims34
At least one chemical entity chosen from compounds of Formula I:
- and pharmaceutically acceptable salts thereof, wherein
- R1 is chosen from phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazolyl, and thiazolyl, each of which is optionally substituted, and each of which is further optionally fused to a heterocyclic or heteroaryl group, each of which is optionally substituted,
- R2 is chosen from substituted aryl and optionally substituted heteroaryl;
- and
- R3 is chosen from hydrogen, lower alkyl, halogen, carboxamido or CO2H, provided that if R2 is 3-(4-(tert-butyl)benzamido)-2-methylphenyl, then R3 is lower alkyl, provided that if R1 is 5-(morpholine-4-carbonyl)-pyridin-2-yl, then R3 is lower alkyl;
- and,
- further provided that the compound of Formula I is not 6-(6-phenyl-imidazo[1,2-a]pyridin-8-ylamino)-nicotinic acid ethyl ester or (6-phenyl-imidazo[1,2-a]pyridin-8-yl)-pyridin-2-yl-amine.
Dependencies are inferred from the claim text.